Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • Zevra Therapeutics' Cost of Revenue fell 4624.4% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 12434.73%. This contributed to the annual value of $7.4 million for FY2024, which is 24132.54% up from last year.
  • Zevra Therapeutics' Cost of Revenue amounted to $1.2 million in Q3 2025, which was down 4624.4% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Cost of Revenue ranged from a high of $12.4 million in Q2 2025 and a low of $8000.0 during Q1 2022
  • Its 5-year average for Cost of Revenue is $1.5 million, with a median of $677000.0 in 2023.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 9490.0% in 2022, then skyrocketed by 547727.27% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Cost of Revenue (Quarter) stood at $59000.0 in 2021, then plummeted by 62.71% to $22000.0 in 2022, then soared by 5477.27% to $1.2 million in 2023, then grew by 11.33% to $1.4 million in 2024, then dropped by 9.37% to $1.2 million in 2025.
  • Its Cost of Revenue stands at $1.2 million for Q3 2025, versus $12.4 million for Q2 2025 and $1.3 million for Q1 2025.